Table of Contents
ISRN Pharmacology
Volume 2012, Article ID 305645, 8 pages
http://dx.doi.org/10.5402/2012/305645
Research Article

Effects of Stimulation and Blockade of D 2 Receptor on Depression-Like Behavior in Ovariectomized Female Rats

Laboratory of Neuroendocrinology, I.P. Pavlov Institute of Physiology of the Russian Academy of Science, 6 Emb. Makarova, 199034 St. Petersburg, Russia

Received 17 November 2011; Accepted 21 December 2011

Academic Editor: M. Alkondon

Copyright © 2012 Julia Fedotova. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Stoppel, H. Bielau, B. Bogerts, and G. Northoff, “Neurobiological basis of depressive disorders,” Fortschritte der Neurologie Psychiatrie, vol. 74, no. 12, pp. 696–705, 2006. View at Publisher · View at Google Scholar · View at PubMed
  2. V. Krishnan and E. J. Nestler, “The molecular neurobiology of depression,” Nature, vol. 455, no. 7215, pp. 894–902, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. P. Olie, E. Costa, J. Silva, and J. P. Macher, Neuroplasticity: A New Approach to the Pathophysiology of Depression, Science Press, London, UK, 2004.
  4. D. A. Slattery, A. L. Hudson, and D. J. Nutt, “Invited review: the evolution of antidepressant mechanisms,” Fundamental and Clinical Pharmacology, vol. 18, no. 1, pp. 1–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. E. J. Nestler and W. A. Carlezon, “The mesolimbic dopamine reward circuit in depression,” Biological Psychiatry, vol. 59, no. 12, pp. 1151–1159, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. J. Nutt, “The role of dopamine and norepinephrine in depression and antidepressant treatment,” Journal of Clinical Psychiatry, vol. 67, supplement 6, pp. 3–8, 2006. View at Google Scholar · View at Scopus
  7. D. J. Nutt, D. S. Baldwin, A. H. Clayton et al., “The role of dopamine and norepinephrine in depression and antidepressant treatment,” Journal of Clinical Psychiatry, vol. 67, supplement 6, pp. 46–49, 2006. View at Google Scholar
  8. B. W. Dunlop and C. B. Nemeroff, “The role of dopamine in the pathophysiology of depression,” Archives of General Psychiatry, vol. 64, no. 3, pp. 327–337, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. W. Kebabian and D. B. Calne, “Multiple receptors for dopamine,” Nature, vol. 277, no. 5692, pp. 93–96, 1979. View at Google Scholar · View at Scopus
  10. B. Giros, M. Jaber, S. R. Jones, R. M. Wightman, and M. G. Caron, “Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter,” Nature, vol. 379, no. 6566, pp. 606–612, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. R. Jones, R. R. Gainetdinov, R. Mark Wightman, and M. G. Caron, “Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter,” Journal of Neuroscience, vol. 18, no. 6, pp. 1979–1986, 1998. View at Google Scholar · View at Scopus
  12. P. Willner, “Dopamine and depression: a review of recent evidence. I. Empirical studies,” Brain Research, vol. 287, no. 3, pp. 211–224, 1983. View at Google Scholar · View at Scopus
  13. J. Maj, “Antidepressants given repeatedly: pharmacological evaluation of their action,” Polish Journal of Pharmacology and Pharmacy, vol. 43, no. 3, pp. 241–254, 1991. View at Google Scholar · View at Scopus
  14. A. S. Brown and S. Gershon, “Dopamine and depression,” Journal of Neural Transmission, vol. 91, no. 2-3, pp. 75–109, 1993. View at Google Scholar · View at Scopus
  15. P. S. D'Aquila, M. Collu, G. L. Gessa, and G. Serra, “The role of dopamine in the mechanism of action of antidepressant drugs,” European Journal of Pharmacology, vol. 405, no. 1–3, pp. 365–373, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Vetulani and I. Nalepa, “Antidepressants: past, present and future,” European Journal of Pharmacology, vol. 405, no. 1–3, pp. 351–363, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Willner, “The mesolimbic dopamine system as a target for rapid antidepressant action,” International Clinical Psychopharmacology, vol. 12, no. 3, pp. S7–S14, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. G. D. Bartoszyk, “Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors,” Life Sciences, vol. 62, no. 7, pp. 649–663, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Niskanen, T. Tamminen, and M. Viukari, “Sulpiride vs. amitriptyline in the treatment of depression,” Current Therapeutic Research, vol. 17, no. 3, pp. 281–284, 1975. View at Google Scholar · View at Scopus
  20. O. Benkert and F. Holsboer, “Effect of sulpiride in endogenous depression,” Acta Psychiatrica Scandinavica, vol. 69, supplement 311, pp. 43–48, 1984. View at Google Scholar
  21. T. Tsukamoto, M. Asakura, T. Tsuneizumi, Y. Satoh, T. Shinozuka, and K. Hasegawa, “Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 18, no. 3, pp. 615–618, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Brunswick, J. D. Amsterdam, P. D. Mozley, and A. Newberg, “Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPECT imaging,” American Journal of Psychiatry, vol. 160, no. 10, pp. 1836–1841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Dhir and S. K. Kulkarni, “Involvement of dopamine (DA)/serotonin (5-HT)/sigma (σ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist,” Brain Research Bulletin, vol. 74, no. 1–3, pp. 58–65, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. C. Gambarana, O. Ghiglieri, A. Tagliamonte, N. D'Alessandro, and M. G. De Montis, “Crucial role of D1 dopamine receptors in mediating the antidepressant effect of imipramine,” Pharmacology Biochemistry and Behavior, vol. 50, no. 2, pp. 147–151, 1995. View at Publisher · View at Google Scholar
  25. C. Gambarana, O. Ghiglieri, and M. G. De Montis, “Desensitization of the D1 dopamine receptors in rats reproduces a model of escape deficit reverted by imipramine, fluoxetine and clomipramine,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 19, no. 5, pp. 741–755, 1995. View at Publisher · View at Google Scholar
  26. M. Cyr, M. Landry, and T. Di Paolo, “Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain,” Neuropsychopharmacology, vol. 23, no. 1, pp. 69–78, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Cyr, F. Calon, M. Morissette, M. Grandbois, S. Callier, and T. Di Paolo, “Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS,” Current Pharmaceutical Design, vol. 6, no. 12, pp. 1287–1312, 2000. View at Google Scholar · View at Scopus
  28. B. B. Sherwin, “Estrogen and cognitive aging in women,” Neuroscience, vol. 138, no. 3, pp. 1021–1026, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. A. A. Walf and C. A. Frye, “Antianxiety and antidepressive behavior produced by physiological estradiol regimen may be modulated by hypothalamic-pituitary-adrenal axis activity,” Neuropsychopharmacology, vol. 30, no. 7, pp. 1288–1301, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. A. Walf and C. A. Frye, “A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior,” Neuropsychopharmacology, vol. 31, no. 6, pp. 1097–1111, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. D. Consoli, J. Fedotova, V. Micale, N. S. Sapronov, and F. Drago, “Stressors affect the response of male and female rats to clomipramine in a model of behavioral despair (forced swim test),” European Journal of Pharmacology, vol. 520, no. 1–3, pp. 100–107, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. Fedotova, “Effects of mild, moderate and severe stress on depression in female rats: modifications by estrous cycle, ovariectomy and estradiol treatment,” Biological Psychiatry and Psychopharmacology, vol. 8, pp. 45–47, 2006. View at Google Scholar
  33. M. Okada, N. Hayashi, M. Kometani, K. Nakao, and T. Inukai, “Influences of ovariectomy and continuous replacement of 17β-estradiol on the tail skin temperature and behavior in the forced swimming test in rats,” Japanese Journal of Pharmacology, vol. 73, no. 1, pp. 93–96, 1997. View at Google Scholar · View at Scopus
  34. T. Pearlstein, K. Rosen, and A. B. Stone, “Mood disorders and menopause,” Endocrinology and Metabolism Clinics of North America, vol. 26, no. 2, pp. 279–294, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. R. E. Noble, “Depression in women,” Metabolism, vol. 54, no. 5, pp. 49–52, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. U. Halbreich and L. S. Kahn, “Role of estrogen in the aetiology and treatment of mood disorders,” CNS Drugs, vol. 15, no. 10, pp. 797–817, 2001. View at Google Scholar · View at Scopus
  37. R. Wang-Cheng and J. A. Rosenfeld, “Hormone replacement therapy,” British Medical Journal, vol. 326, pp. 139–140, 2003. View at Google Scholar
  38. T. Di Paolo, P. Poyet, and F. Labrie, “Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors,” European Journal of Pharmacology, vol. 73, no. 1, pp. 105–106, 1981. View at Google Scholar · View at Scopus
  39. C. L. Smith, O. M. Conneely, and B. W. O'Malley, “Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 6120–6124, 1993. View at Google Scholar · View at Scopus
  40. S. K. Mani, J. D. Blaustein, and B. W. O'Malley, “Progesterone receptor function from a behavioral perspective,” Hormones and Behavior, vol. 31, no. 3, pp. 244–255, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. J. E. Riby, G. H. F. Chang, G. L. Firestone, and L. F. Bjeldanes, “Ligand-independent activation of estrogen receptor function by 3,3'-diindolylmethane in human breast cancer cells,” Biochemical Pharmacology, vol. 60, no. 2, pp. 167–177, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. R. D. Porsolt, A. Bertin, and M. Jalfre, “'Behavioral despair' in rats and mice: strain differences and the effects of imipramine,” European Journal of Pharmacology, vol. 51, no. 3, pp. 291–294, 1978. View at Google Scholar · View at Scopus
  43. C. Leranth, R. H. Roth, J. D. Elswoth, F. Naftolin, T. L. Horvath, and D. E. Redmond, “Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory,” Journal of Neuroscience, vol. 20, no. 23, pp. 8604–8609, 2000. View at Google Scholar · View at Scopus
  44. Q. D. Walker, J. Cabassa, K. A. Kaplan et al., “Sex differences in cocaine-stimulated motor behavior: disparate effects of gonadectomy,” Neuropsychopharmacology, vol. 25, no. 1, pp. 118–130, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. R. Ponnusamy, H. A. Nissim, and M. Barad, “Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice,” Learning and Memory, vol. 12, no. 4, pp. 399–406, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. M. L. Johnson, C. C. Ho, A. E. Day, Q. D. Walker, R. Francis, and C. M. Kuhn, “Oestrogen receptors enhance dopamine neurone survival in rat midbrain,” Journal of Neuroendocrinology, vol. 22, no. 4, pp. 226–237, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. E. Estrada-Camarena, A. Fernández-Guasti, and C. López-Rubalcava, “Antidepressant-like effect of different estrogenic compounds in the forced swimming test,” Neuropsychopharmacology, vol. 28, no. 5, pp. 830–838, 2003. View at Google Scholar
  48. E. Estrada-Camarena, A. Fernández-Guasti, and C. López-Rubalcava, “Interaction between estrogens and antidepressants in the forced swimming test in rats,” Psychopharmacology, vol. 173, no. 1, pp. 139–145, 2004. View at Publisher · View at Google Scholar · View at PubMed
  49. J. Fedotova and N. Platonova, “Behavioral response to clomipramine after application of different stressors in ovariectomized female rats,” European Neuropsychopharmacology, vol. 17, supplement 4, 368 pages, 2007. View at Google Scholar
  50. K. Takamori, S. Yoshida, and S. Okuyama, “Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test,” Life Sciences, vol. 69, no. 16, pp. 1919–1926, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. M. M. Robertson and M. R. Trimble, “Neuroleptics as antidepressants,” Neuropharmacology, vol. 20, no. 12 B, pp. 1335–1336, 1981. View at Google Scholar · View at Scopus
  52. A. I. Abbas, P. B. Hedlund, X. P. Huang, T. B. Tran, H. Y. Meltzer, and B. L. Roth, “Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo,” Psychopharmacology, vol. 205, no. 1, pp. 119–128, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. G. R. Pawar, R. P. Agrawal, P. Phadnis, A. Paliwal, S. Vyas, and P. Solanki, “Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice,” Acta Poloniae Pharmaceutica, vol. 66, no. 3, pp. 327–331, 2009. View at Google Scholar · View at Scopus
  54. E. M. Nikulina, J. A. Skrinskaya, and N. K. Popova, “Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test,” Psychopharmacology, vol. 105, no. 4, pp. 525–529, 1991. View at Google Scholar · View at Scopus
  55. T. Silverstone, “Response to bromocriptine distinguishes bipolar from unipolar depression,” The Lancet, vol. 1, no. 8382, pp. 903–904, 1984. View at Google Scholar · View at Scopus
  56. F. Borsini, A. Lecci, A. Mancinelli, V. D'Aranno, and A. Meli, “Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity,” European Journal of Pharmacology, vol. 148, no. 3, pp. 301–307, 1988. View at Google Scholar · View at Scopus
  57. C. A. Tamminga and J. Gerlach, “New neuroleptics and experimental antipsychotics in schizophrenia,” in Psychopharmacology, Herbert Y. Meltzer, Ed., pp. 1129–1140, Raven press, New York, NY, USA, 1987. View at Google Scholar
  58. A. Tagliamonte, G. De Montis, M. Olianas, L. Vargiu, G. U. Corsini, and G. L. Gessa, “Selective increase of brain dopamine synthesis by sulpiride,” Journal of Neurochemistry, vol. 24, no. 4, pp. 707–710, 1975. View at Google Scholar
  59. H. M. A. S. Standish Barry, N. Bouras, P. K. Bridges, and J. P. Watson, “A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder,” Psychopharmacology, vol. 81, no. 3, pp. 258–260, 1983. View at Google Scholar · View at Scopus
  60. J. L. Mouret, P. Le Moine, and M. P. Minuit, “Marquers polygraphiques Clinique et therapeutique des depressions dopamine-dependantes (DDD) (special issue),” Confront Psychiatr, pp. 430–437, 1989. View at Google Scholar
  61. J. C. Nelson, “The use of antipsychotic drugs in the treatment of depression,” in Treating Resistant Depression, J. Zohar and R. H. Belmaker, Eds., pp. 131–146, PMA Corp, New York, NY, USA, 1987. View at Google Scholar
  62. B. Levant, “The D3 dopamine receptor: neurobiology and potential clinical relevance,” Pharmacological Reviews, vol. 49, no. 3, pp. 231–252, 1997. View at Google Scholar · View at Scopus
  63. A. Imperato and G. Di Chiara, “Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis,” Journal of Neuroscience, vol. 5, no. 2, pp. 297–306, 1985. View at Google Scholar · View at Scopus
  64. B. Moghaddam and B. S. Bunney, “Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 14, supplement, pp. S51–S57, 1990. View at Publisher · View at Google Scholar · View at Scopus
  65. K. T. Kawagoe, P. A. Garris, D. J. Wiedemann, and R. M. Wightman, “Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum,” Neuroscience, vol. 51, no. 1, pp. 55–64, 1992. View at Publisher · View at Google Scholar · View at Scopus